Literature DB >> 26914083

[Subcutaneous fat necrosis and persistent hypercalcaemia in a newborn treated with therapeutic neonatal hypothermia. A case report].

José M Martínez de Zabarte Fernández1, Sara Laliena Aznar2, Elena Corella Aznar2, Laura Cuadrado Piqueras2, María J Oliván del Cacho2, Raquel Pinillos Pisón2.   

Abstract

Therapeutic hypothermia is the current standard treatment in newborns with moderate to severe hypoxic-ischemic encephalopathy, changing the outcome of these children. It is considered a safe technique with almost no side effects. A possible adverse side event is subcutaneous fat necrosis, which is an acute self-limiting panniculitis that develops during the first weeks of life. We report a case of a newborn at term suffering hypoxic-ischemic encephalopathy with a generalized multiform erythematous rash and firm and indurated plaques over the back, buttocks and extremities on his 12th day of life after being treated with therapeutic hypothermia. Histopathological study after skin punchbiopsy confirmed the suspicion of subcutaneous fat necrosis. The infant developed asymptomatic moderate hypercalcaemia within the first month of life, which was treated with intravenous fluids and diuretics. Serum calcium levels decreased and normalized in 3 months, with progressive disappearance of skin lesions. Sociedad Argentina de Pediatría.

Entities:  

Keywords:  Hypercalcaemia; Hypoxic-ischemic encephalopathy; Newborn; Subcutaneous fat necrosis; Therapeutic hypothermia

Mesh:

Year:  2016        PMID: 26914083     DOI: 10.5546/aap.2016.e13

Source DB:  PubMed          Journal:  Arch Argent Pediatr        ISSN: 0325-0075            Impact factor:   0.635


  2 in total

Review 1.  Hypercalcemia: a consultant's approach.

Authors:  Ari Auron; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2017-09-06       Impact factor: 3.714

2.  Subcutaneous fat necrosis of the newborn - An atypical case with typical complications.

Authors:  Cristina Lorenzo; Andreia Romana; Joana Matias; Paulo Calhau
Journal:  Clin Case Rep       Date:  2021-02-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.